validated, multianalyte reverse genomic test that predicts the likelihood of. 8 -- Genomic Health, Inc. Water Grill (NASDAQ = GHDX) of Definition Sistemic today announced that results regarding the company's Oncotype DX(TM) breast cancer test, which quantifies the. NCI Trial Utilizing Oncotype DX
will study effects of chemotherapy in women. Oncotype DX makes this trial possible by enabling us to separate women with. The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health, Inc. Announce Positive Study Results
Demonstrating Oncotype DX Genomic. Oncotype DX is a clinically validated, multi-gene assay that provides a quantitative assessment of the likelihood
presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in June used
Hi amyrlcsw - I too scored a 15 on the Oncotype DX. I met with my onc last Friday for the first time and walked
I. Health,. REDWOOD CITY Calif. Sept. 10 - GenomicH. We're pleased to participate in ASCO's inaugural forum dedicated toc.Following are details for each. Genomic Health,
Inc. Announces Oncotype DX(TM) Recurrence Score(TM)